Mitogen Diagnostics Corporation (MitogenDx) exists to make a positive impact on people’s health through expertise in leading edge diagnostic technologies. We embrace precision health initiatives and provide patient-centered diagnostic information. Beginning in 1984, MitogenDx now provides a spectrum of over 500 diagnostic targets specializing in autoimmune diagnostic tests and immune biomarkers.
Our goal is to HELP:
MitogenDx specializes in the identification of novel autoantibodies and other proteomic biomarkers for autoimmune diseases. In turn, Mitogen develops new diagnostic tests for the detection of autoantibodies and autoantigens in biological fluids. A large part of Mitogen’s R&D successes are due to the company’s specialization in antigen purification and production. The characterization of intracellular antigens that react with sera of patients with systemic rheumatic and other autoimmune disease has led to the development of many novel esoteric diagnostic tests.
Through Mitogen’s diagnostic services the role of environmental xenobiotics in the induction and perpetuation of autoimmunity is brought into great consideration.